Ann: Quarterly Activity Report & Appendix 4C, page-23

Maybe they think you've been ramping too much .

in their defense, looking at it from a lay perspective, this isn't entirely relevant to our core strategy ie cancer(I realise it further reaffirms FTO in a human's overall disease process). And it isn't a new finding per se, as we know zantrene and FTO is linked(twice already independently).

While I agree it further reaffirms the Zantrene and FTO link, from what I can see, diabetes isn't on the cards for any clinical trials. A lot of posters here have been prematurely excited off this paper, but there is still a lot of work to be done before there would be a tangible return, IMO.

with that said, you did say you deemed it as not price sensitive, so I'm not sure how it's ramping.

This from a non scientific POV, Dr T.. I'm happy for you to correct me if you think otherwise.